292 related articles for article (PubMed ID: 16509932)
21. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
22. [Complete cytogenetic response to interferon-alpha in a patient with chronic myelogenous leukemia undergoing hemodialysis].
Doi S; Edamura S; Akasaka H; Kawamura M; Arima N; Nasu K
Rinsho Ketsueki; 2001 Jul; 42(7):549-53. PubMed ID: 11524845
[TBL] [Abstract][Full Text] [Related]
23. Interferon-alpha lymphoblastoid in chronic myeloid leukemia patients unresponsive to recombinant IFN alpha 2.
Steegmann JL; Granados E; Peñarrubia MJ
Haematologica; 1997; 82(6):731-2. PubMed ID: 9580090
[No Abstract] [Full Text] [Related]
24. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
Breccia M; Diverio D; Pane F; Nanni M; Russo E; Biondo F; Frustaci A; Gentilini F; Alimena G
Leuk Res; 2006 Dec; 30(12):1577-9. PubMed ID: 16630657
[TBL] [Abstract][Full Text] [Related]
25. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
26. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
Volkova SA; Prytkova MV; Borovkov NN
Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
[TBL] [Abstract][Full Text] [Related]
27. Thrombotic thrombocytopenic purpura complicating chronic myelogenous leukemia treated with interferon-alpha. A report of two successfully treated patients.
Rachmani R; Avigdor A; Youkla M; Raanani P; Zilber M; Ravid M; Ben-Bassat I
Acta Haematol; 1998; 100(4):204-6. PubMed ID: 9973644
[TBL] [Abstract][Full Text] [Related]
28. Reversible leg ulcer due to hydroxyurea in a case of chronic myeloid leukemia.
Tripathi AK; Ahmad R; Sawlani KK
J Assoc Physicians India; 2003 Oct; 51():1014-5. PubMed ID: 14719596
[TBL] [Abstract][Full Text] [Related]
29. [Hemolitic uremic syndrome with hypertransaminasemia following treatment by interferon for chronic myeloid leukemia].
Denizon N; Beraud JJ; Mourad G; Blanc P; Bureau JP; Navarro M; Lavabre-Bertrand T
Gastroenterol Clin Biol; 2001 Nov; 25(11):1039-40. PubMed ID: 11845064
[No Abstract] [Full Text] [Related]
30. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
[TBL] [Abstract][Full Text] [Related]
31. [Ulcers on the legs and feet: a seldom recognised side effect of hydroxyurea].
Janssen JJ; Ossenkoppele GJ
Ned Tijdschr Geneeskd; 2003 Aug; 147(31):1517-20. PubMed ID: 12924084
[TBL] [Abstract][Full Text] [Related]
32. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia.
Ladoyanni E; Nambi R
J Drugs Dermatol; 2005; 4(2):221-2. PubMed ID: 15776781
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
34. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha.
Steegmann JL; Requena MJ; Martín-Regueira P; De La Cámara R; Casado F; Salvanés FR; Fernández Rañada JM
Am J Hematol; 2003 Mar; 72(3):170-6. PubMed ID: 12605388
[TBL] [Abstract][Full Text] [Related]
35. [Reversible cardiomyopathy secondary to interferon-alpha in chronic myelogenous leukemia].
Uehara E; Uesugi T; Tasaka T; Matsuhashi Y; Tamura T; Kuwajima M; Nagai M
Gan To Kagaku Ryoho; 2002 Feb; 29(2):317-21. PubMed ID: 11865642
[TBL] [Abstract][Full Text] [Related]
36. [The role of alpha-interferon therapy in chronic myeloid leukemia].
Udvardy M
Orv Hetil; 2000 Jan; 141(2):67-70. PubMed ID: 10686779
[TBL] [Abstract][Full Text] [Related]
37. [Effectiveness of treatment with native alpha-interferon (Wellferon) in patients with chronic myeloid leukemia].
Rukavitsyn OA
Vopr Onkol; 1997; 43(6):606-9. PubMed ID: 9479361
[No Abstract] [Full Text] [Related]
38. Behçet's disease induced by interferon therapy for chronic myelogenous leukemia.
Segawa F; Shimizu Y; Saito E; Kinoshita M
J Rheumatol; 1995 Jun; 22(6):1183-4. PubMed ID: 7674251
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period.
Giona F; Moleti ML; Del Giudice I; Testi AM; Diverio D; De Cuia MR; Mandelli F; Foa R
Br J Haematol; 2005 Sep; 130(6):970-2. PubMed ID: 16156873
[No Abstract] [Full Text] [Related]
40. Renal thrombotic microangiopathy induced by interferon-alpha.
Badid C; McGregor B; Faivre JM; Guerard A; Juillard L; Fouque D; Laville M
Nephrol Dial Transplant; 2001 Apr; 16(4):846-8. PubMed ID: 11274286
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
